Ayala reports Phase Ib data for AL101 in solid tumors

Ayala Pharmaceuticals Inc. (Rehovot, Israel) said once-weekly 4 mg IV AL101 (formerly BMS-906024) led to a complete response in a

Read the full 201 word article

User Sign In